Correction to: Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities

Norina Tanaka¹ · Yoichi Imai² · Kentaro Yoshinaga¹ · Masayuki Shiseki¹ · Junji Tanaka¹

Published online: 26 September 2020

© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Correction to: Annals of Hematology

<https://doi.org/10.1007/s00277-020-04267-0>

In the published online paper, the data “ $p = 0.144$ ” was not deleted from the line “Median and mean number of prior treatments (range)” in Table 4. The publisher wish to apologize for this oversight.

The original article has been corrected.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1007/s00277-020-04267-0>

✉ Yoichi Imai
imaiyo-ky@umin.ac.jp

¹ Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan

² Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan